JAC Advance Access originally published online on February 25, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2004) 53, 669-674
© 2004 The British Society for Antimicrobial Chemotherapy
Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms
1 The JONES Group/JMI Laboratories, Inc., 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317; 2 Tufts University School of Medicine, Boston, MA, USA
Received 21 October 2003; returned 24 November 2003; revised 8 January 2004; accepted 15 January 2004
Background: Increasing antimicrobial resistance among bacterial pathogens has prompted attempts to develop new antimicrobial agents active against multidrug-resistant Gram-positive pathogens.
Objectives: To evaluate the in vitro activity of daptomycin against a worldwide collection of clinical bacterial isolates.
Methods: Daptomycin is a novel cyclic lipopeptide recently approved by the United States Food and Drug Administration. Daptomycin and selected comparators were tested against 6737 clinical Gram-positive strains from more than 70 centres located in Europe, North America and South America.
Results: The overall distribution of daptomycin MIC values were in the range 
0.12–8 mg/L and 99.4% of all strains were inhibited at 2 mg/L. Despite resistances to other antimicrobial agents, >99.9% of staphylococcal isolates were inhibited at 1 mg/L of daptomycin (MIC90 0.5 mg/L for staphylococci). Streptococcal isolates were very susceptible to daptomycin independent of their susceptibility to penicillin. MIC50/90 values were 0.12 and 0.25 mg/L, respectively. Enterococci showed the highest daptomycin MIC values, but all isolates tested were inhibited at 4 mg/L (except for one Enterococcus faecium isolate which showed a daptomycin MIC of 8 mg/L).
Conclusions: Daptomycin exhibited excellent in vitro activity against a wide spectrum of Gram-positive organisms and may represent a therapeutic option for infections caused by multidrug-resistant pathogens worldwide.
Keywords: resistance, glycopeptides, multidrug-resistant
* Corresponding author. Tel: +1-319-665-3370; Fax: +1-319-665-3371; Email: helio-sader{at}jmilabs.com
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Schoen, C. Unzicker, G. Stuhler, J. Elias, H. Einsele, G. U. Grigoleit, M. Abele-Horn, and S. Mielke Life-Threatening Infection Caused by Daptomycin-Resistant Corynebacterium jeikeium in a Neutropenic Patient J. Clin. Microbiol., July 1, 2009; 47(7): 2328 - 2331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Swenson, K. F. Anderson, D. R. Lonsway, A. Thompson, S. K. McAllister, B. M. Limbago, R. B. Carey, F. C. Tenover, and J. B. Patel Accuracy of Commercial and Reference Susceptibility Testing Methods for Detecting Vancomycin-Intermediate Staphylococcus aureus J. Clin. Microbiol., July 1, 2009; 47(7): 2013 - 2017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Seaton Daptomycin: rationale and role in the management of skin and soft tissue infections J. Antimicrob. Chemother., November 1, 2008; 62(suppl_3): iii15 - iii23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Spanjaard and C. M. J. E. Vandenbroucke-Grauls Activity of Daptomycin against Listeria monocytogenes Isolates from Cerebrospinal Fluid Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1850 - 1851. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Sakoulas, W. Rose, M. J. Rybak, S. Pillai, J. Alder, R. C. Moellering Jr., and G. M. Eliopoulos Evaluation of Endocarditis Caused by Methicillin-Susceptible Staphylococcus aureus Developing Nonsusceptibility to Daptomycin J. Clin. Microbiol., January 1, 2008; 46(1): 220 - 224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-T. Huang, C.-H. Liao, L.-J. Teng, and P.-R. Hsueh Daptomycin Susceptibility of Unusual Gram-Positive Bacteria: Comparison of Results Obtained by the Etest and the Broth Microdilution Method Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1570 - 1572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Jevitt, G. M. Thorne, M. M. Traczewski, R. N. Jones, J. E. McGowan Jr., F. C. Tenover, and S. D. Brown Multicenter Evaluation of the Etest and Disk Diffusion Methods for Differentiating Daptomycin-Susceptible from Non-Daptomycin-Susceptible Staphylococcus aureus Isolates. J. Clin. Microbiol., September 1, 2006; 44(9): 3098 - 3104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Denis, A. Deplano, C. Nonhoff, M. Hallin, R. De Ryck, R. Vanhoof, R. De Mendonca, and M. J. Struelens In Vitro Activities of Ceftobiprole, Tigecycline, Daptomycin, and 19 Other Antimicrobials against Methicillin-Resistant Staphylococcus aureus Strains from a National Survey of Belgian Hospitals. Antimicrob. Agents Chemother., August 1, 2006; 50(8): 2680 - 2685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. Marty, W. W. Yeh, C. B. Wennersten, L. Venkataraman, E. Albano, E. P. Alyea, H. S. Gold, L. R. Baden, and S. K. Pillai Emergence of a Clinical Daptomycin-Resistant Staphylococcus aureus Isolate during Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia and Osteomyelitis J. Clin. Microbiol., February 1, 2006; 44(2): 595 - 597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Pankey, D. Ashcraft, and N. Patel In Vitro Synergy of Daptomycin plus Rifampin against Enterococcus faecium Resistant to both Linezolid and Vancomycin Antimicrob. Agents Chemother., December 1, 2005; 49(12): 5166 - 5168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Vikram, N. L. Havill, L. M. Koeth, and J. M. Boyce Clinical Progression of Methicillin-Resistant Staphylococcus aureus Vertebral Osteomyelitis Associated with Reduced Susceptibility to Daptomycin J. Clin. Microbiol., October 1, 2005; 43(10): 5384 - 5387. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. Steenbergen, J. Alder, G. M. Thorne, and F. P. Tally Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections J. Antimicrob. Chemother., March 1, 2005; 55(3): 283 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Lipsky and U. Stoutenburgh Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections J. Antimicrob. Chemother., February 1, 2005; 55(2): 240 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Novais, J. C. Sousa, T. M. Coque, L. V. Peixe, and on behalf of the Portuguese Resistance Study Group In vitro activity of daptomycin against enterococci from nosocomial and community environments in Portugal J. Antimicrob. Chemother., November 1, 2004; 54(5): 964 - 966. [Full Text] [PDF]
|
|